Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies.
ELISA
digital immunostaining
nCounter
programmed death ligand-1
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
13
08
2018
accepted:
09
01
2019
entrez:
9
3
2019
pubmed:
9
3
2019
medline:
9
3
2019
Statut:
ppublish
Résumé
One obstacle in diagnostic pathology is the harmonization of one drug-one diagnostic tests for programmed death ligand-1 (PD-L1). There are many challenges in accurate comparisons of diagnostic tests, such as differences in the titer of each antibody, detection system and dynamic range of visualization. Our previously developed digital immunostaining technique is highly sensitive and quantitative with the ability to quantify particles that bind in a one-to-one fashion with antibody in each cell. Determining the differences in the titer of each antibody with digital immunostaining may be beneficial for future harmonized analysis. To demonstrate the accuracy of digital immunostaining, the present study compared the number of particles with ELISA and nCounter data from five cell lines. NCI-H460 exhib-ited the highest level of PD-L1 protein, followed by A549, PC-3, NCI-H1299, and NCI-H446 cells. In addition, the PD-L1 mRNA values determined by nCounter corresponded with the order of the protein levels determined by ELISA. The present study revealed that digital immunostaining for PD-L1 was highly associated with ELISA and nCounter data. Among the four antibodies tested, the titer of all but SP142 coincided with ELISA and nCounter data. These results indicated that our digital immunostaining technique may be beneficial for future harmonized analysis.
Identifiants
pubmed: 30847180
doi: 10.3892/mco.2019.1801
pii: MCO-0-0-1801
pmc: PMC6388504
doi:
Types de publication
Journal Article
Langues
eng
Pagination
391-396Références
Mol Cell Proteomics. 2002 Apr;1(4):304-13
pubmed: 12096112
Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):90-6
pubmed: 19661787
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Biochem Biophys Res Commun. 2012 Sep 28;426(3):409-14
pubmed: 22959769
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
PLoS One. 2016 Apr 22;11(4):e0153954
pubmed: 27104612
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Oncotarget. 2017 Feb 28;8(9):15584-15592
pubmed: 28107186
Int J Clin Oncol. 2017 Aug;22(4):726-733
pubmed: 28314962
Sci Rep. 2017 Aug 8;7(1):7509
pubmed: 28790306